https://www.thebusinessresearchcompany.com/report/sarclisa-global-market-report
Sarclisa Market Report 2026, Research And Industry Share To 2035
The Sarclisa market is witnessing steady growth over the forecast period, supported by increasing investments in next-generation oncology drugs, growing focus...
research and industrymarket reportsarclisa2026share
https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-03-20-15-00-2892607
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival...
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple...
https://www.sanofi.com/en/media-room/press-releases/2025/2025-01-13-06-00-00-3008102
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with...
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal...
https://www.sanofi.com/en/media-room/press-releases/2024/2024-08-08-05-00-00-2926566
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free...
Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for...
press releaseinduction treatmentsarclisademonstratedsignificantly
https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-23-05-00-00-3103085
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly...
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study...
https://www.sanofi.com/fi/suomi/sarclisa
Sarclisa
sarclisa
https://www.sanofi.com/en/media-room/press-releases/2024/2024-11-14-16-42-42-2981448
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible...
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study...